Table 1.
Characteristics of patients in the study population and according to subgroup, and comparison of the standardized difference values for the main characteristics, according to the type of analysis.
| Characteristic | Overall: N (%) | No-PC-LND: N (%) | PC-LND: N (%) | Unweighted standardized difference (%) | Standardized difference after IPTW (%) | Standardized difference after 1:1 matching (%) |
|---|---|---|---|---|---|---|
|
| ||||||
| Total number of patients | 522 | 280 | 242 | 522 | 522 | 84 |
|
| ||||||
| Age at diagnosis: median years (IQR) | 64 (57–70) | 67 (60–73) | 61 (53–67) | 59.26 | 9.87 | 9.87 |
|
| ||||||
| Smoking history: | ||||||
| Never smoker | 122 (24.7) | 68 (24.3) | 54 (25.2) | 4.74 | ||
| Former smoker | 229 (46.4) | 143 (51.1) | 86 (40.2) | 32.46 | NA* | NA* |
| Current smoker | 143 (28.9) | 69 (24.6) | 74 (34.6) | 12.88 | ||
| Missing | 28 | - | 28 | 36.17 | ||
|
| ||||||
| ECOG-PS:** | ||||||
| 0 | 235 (53.9) | 104 (44.4) | 131 (64.8) | 34.10 | 15.78 | −4.76 |
| 1 | 159 (36.5) | 100 (42.7) | 59 (29.2) | 26.51 | 26.15 | −2.52 |
| ≥2 | 42 ( 9.6) | 30 (12.9) | 12 (6.0) | 26.51 | 11.50 | −17.19 |
| Missing | 86 | 46 | 40 | 0.27 | 15.78 | 24.27 |
|
| ||||||
| Clinical T stage: | ||||||
| T1–2 | 268 (52.3) | 172 (61.4) | 96 (41.4) | 44.48 | 33.17 | −4.78 |
| T3–4 | 244 (47.7) | 108 (38.6) | 136 (58.6) | 35.53 | 24.38 | −4.78 |
| Missing | 10 | - | 10 | 20.76 | - | - |
|
| ||||||
| Lymph node extent: | ||||||
| Pelvic LN | 345 (66.1) | 164 (58.6) | 181 (74.8) | 37.36 | 27.16 | −9.89 |
| RP LN | 177 (33.9) | 116 (41.4) | 61 (25.2) | 37.36 | 27.16 | −9.89 |
|
| ||||||
| Prior local treatment: | ||||||
| No | 283 (64.0) | 136 (48.6) | 147 (90.7) | 24.93 | 40.94 | −20.39 |
| Yes | 159 (36.0) | 144 (51.4) | 15 (9.3) | 187.58 | 54.17 | 20.39 |
| Missing | 80 | - | 80 | 70.27 | 70.27 | - |
|
| ||||||
| Prior perioperative CT: | ||||||
| No | 467 (89.5) | 232 (82.9) | 235 (97.1) | 85.03 | 36.18 | 15.81 |
| Yes | 55 (10.5) | 48 (17.1) | 7 (2.9) | 85.03 | 36.18 | −15.81 |
|
| ||||||
| Type of CT: | ||||||
| Cisplatin-based | 386 (75.7) | 194 (69.3) | 192 (83.5) | 24.83 | 0.41 | −11.80 |
| Carboplatin-based | 124 (24.3) | 86 (30.7) | 38 (16.5) | 41.26 | 14.08 | 11.80 |
| Missing | 12 | - | 12 | 22.84 | 22.84 | - |
|
| ||||||
| Best response to CT: | ||||||
| CR | 79 (19.9) | 35 (16.0) | 44 (24.7) | 14.73 | 2.96 | 0.00 |
| PR | 188 (47.4) | 78 (35.6) | 110 (61.8) | 35.34 | 5.54 | 16.62 |
| SD | 81 (20.4) | 62 (28.3) | 19 (10.7) | 53.13 | 28.45 | −12.07 |
| PD | 49 (12.3) | 44 (20.1) | 5 (2.8) | 95.95 | 52.04 | 0.00 |
| Missing | 125 | 61 | 64 | 10.57 | 37.80 | −13.31 |
Abbreviations: CR: complete response; CT: chemotherapy; ECOG-PS: Eastern Cooperative Oncology Group Performance Status: IPTW: inverse probability of treatment weighting; IQR: interquartile range; LN: lymph node; NA: not available; PC-LND: postchemotherapy lymphadenectomy; PD: progressive disease; PR: partial response; RP: retroperitoneal; SD: stable disease.
*
Not considered for propensity score weighting and matching analyses.
**
Assessed after chemotherapy completion (i.e., at the time of surgery in operated patients).